for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Krka d.d. Novo Mesto

KRKG.LJ

Latest Trade

64.60EUR

Change

0.20(+0.31%)

Volume

2,571

Today's Range

64.20

 - 

64.80

52 Week Range

53.60

 - 

65.00

As of on the Ljubljana Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
64.40
Open
64.20
Volume
2,571
3M AVG Volume
0.14
Today's High
64.80
Today's Low
64.20
52 Week High
65.00
52 Week Low
53.60
Shares Out (MIL)
31.77
Market Cap (MIL)
2,118.46
Forward P/E
10.82
Dividend (Yield %)
4.95

Next Event

Q3 2019 Krka dd Novo Mesto Earnings Release

Latest Developments

More

Krka dd Novo Mesto says dispute regarding esomeprazole in the Great Britain ended

Krka dd Novo Mesto receives decision by the European Commission regarding perindopril

Krka dd Novo Mesto proposes dividend for FY 2013

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Krka d.d. Novo Mesto

Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.

Industry

Biotechnology & Drugs

Contact Info

Smarjeska cesta 6

+386.7.3312111

http://www.krka.si/

Executive Leadership

Joze Colaric

Chief Executive Officer and Chairman (President) of the Management Board

Franc Sasek

Independent Deputy Chairman (President) of the Supervisory Board - Employees' Representative

Andrej Slapar

Independent Deputy Chairman (President) of the Supervisory Board - Shareholders' Representative

David Bratoz

Member of the Management Board

Milena Kastelic

Member of the Management Board, Worker Director; Head of Semi-Solid, Liquid and Other Products and Head of Bršljin Department

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

1.2K

2017

1.3K

2018

1.3K

2019(E)

1.4K
EPS (EUR)

2016

3.350

2017

4.740

2018

5.460

2019(E)

5.968
Price To Earnings (TTM)
9.58
Price To Sales (TTM)
1.50
Price To Book (MRQ)
1.22
Price To Cash Flow (TTM)
6.57
Total Debt To Equity (MRQ)
1.40
LT Debt To Equity (MRQ)
1.28
Return on Investment (TTM)
12.00
Return on Equity (TTM)
10.17

Latest News

Latest News

Slovenian export growth boosted by pharmaceuticals -government institute

Slovenia's export growth remains strong, mainly due to exports of pharmaceutical products, despite global economic risks and expected lower growth in the country's main trading partners, the government's macroeconomic institute said.

UPDATE 1-Slovenian drugmaker Krka reports 37% jump in H1 net profit

Slovenia's Krka made a group net profit of 139.9 million euros ($158 million) in the first half of the year, up 37% from a year earlier, the generic drugs producer said in a statement on Thursday.

Slovenian drugmaker Krka reports 37% jump in H1 net profit

Slovenia's Krka made a group net profit of 139.9 million euros ($158 million) in the first half of the year, up 37% from a year earlier, the generic drugs producer said on Thursday.

UPDATE 1-Slovenian drugmaker Krka Q1 profit jumps by 42% as sales rise

Slovenian generic drugs producer Krka made a group net profit of 70.3 million euros ($78.4 million) in the first quarter of 2019 versus 49.4 million euros in the same period last year, Krka said in a statement on Thursday.

Slovenian drugmaker Krka Q1 profit jumps by 42%

Slovenian generic drugs producer Krka made a group net profit of 70.3 million euros ($78.4 million) in the first quarter of 2019 versus 49.4 million euros in the same period last year, Krka said in a statement on Thursday.

Slovenia's Krka to raise dividend by 10 pct

Slovenian pharmaceutical producer Krka plans to pay a dividend of 3.2 euros ($3.61) per share later this year, up from 2.9 euros in 2018, the company said in a statement on Thursday.

Slovenia's Krka 2018 group net profit up by 14 pct

Slovenia's pharmaceutical company Krka made group net profit of 174 million euros ($198.17 million) versus 152.6 million a year before on higher sales, the company said on Thursday.

UPDATE 1-Slovenia's Krka reports 10 pct rise in profit in Jan-Sept period

* 2019 sales seen at 1.4 billion euros (Updates with quote, details)

Slovenia's Krka Jan-Sept group profit up 10 pct

Slovenia's generic drugs producer Krka made a group net profit of 120.8 million euros ($137.76 million) in the first nine months of 2018, up from 110.1 million a year before, the company said in a report on Thursday.

UPDATE 1-Slovenian drugmaker Krka revises first-half profit slightly higher

Slovenian generic drugs producer Krka revised its first-half net profit slightly higher on Thursday and said it was on track to meet its full-year targets.

Slovenian drugmaker Krka reports 11 pct rise in first-half profit

Slovenia's generic drugs producer Krka made a group net profit of 101.7 million euros ($119 million) in the first half of 2018, slightly more than 101.4 mln euros it estimated in early July, Krka said in a statement on Thursday.

UPDATE 1-Slovenian drug company Krka's profits up by 11 pct in first half

Slovenian generic drug producer Krka reported an 11 percent rise in first-half group net profit of 101.4 million euros($119 million), the company said in a statement on Thursday.

Slovenia's Krka says H1 group net profit up by 11 pct

Slovenian drug producer Krka reported an 11 percent rise in first-half group net profit of 101.4 million euros($119 million), first estimates showed, the company said in a statement on Thursday.

UPDATE 1-Slovenian drugmaker Krka reports 16 pct jump in Q1 group net profit

Slovenian generic drugs producer Krka reported a 16 percent jump in first-quarter net profit to 49.4 million euros ($58.08 million) due to higher sales and cost cutting.

Slovenian drugmaker Krka reports 16 pct jump in Q1 group net profit

Slovenian generic drugs producer Krka reported net profit of 49.4 million euros ($58.08 million) in the first quarter of 2018 compared with 42.7 million last year.

Slovenian drugmaker Krka to raise dividend by 5.5 pct

Slovenian generic drugs producer Krka said it plans to pay a dividend of 2.9 euros ($3.59) per share this year versus 2.75 euros paid last year.

UPDATE 1-Slovenia's Krka 2017 net profit jumps 41 percent

Higher sales helped Slovenian generic drug producer Krka post a preliminary 2017 group net profit of 152.6 million euros ($187.9 million), up 41 percent from 2016.

Slovenia's Krka 2017 net profit jumps 41 percent

Slovenian generic drug producer Krka made a preliminary 2017 group net profit of 152.6 million euros ($187.9 million), up 41 percent from 2016, the company said on Thursday.

UPDATE 1-Slovenia's Krka sees 2018 profit up, forms China joint venture

* Expects 2017 net of 140 mln, 153 mln in 2018 (Recasts with forecasts, China joint venture)

BRIEF-Ningbo Menovo Pharmaceutical to set up JV in China with Slovenia's KRKA

Ningbo Menovo Pharmaceutical Co Ltd * Says it plans to set up JV in China with Slovenia's KRKA Source text in Chinese: http://bit.ly/2jtgV1n Further company coverage: (Reporting by Hong Kong newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up